Bristol-Myers Squibb vs Eli Lilly: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Eli Lilly
- Founded
- 1876
- Headquarters
- Indianapolis, Indiana
- Current CEO
- David A. Ricks
- Employees
- 50,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Eli Lilly
Colonel Eli Lilly
Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Eli Lilly
- Randall L. Tobias1993–1998
Chairman and Chief Executive Officer
Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.
Source - Sidney Taurel1998–2008
Former Chair and CEO
Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.
Source - John C. Lechleiter2008–2016
Chairman, President and CEO
Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.
Source - David A. Ricks2017–present
Chair and Chief Executive Officer
Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.
Source
Timeline: Bristol-Myers Squibb and Eli Lilly side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1876Eli Lilly
Eli Lilly Founded
Colonel Eli Lilly founds the company in Indianapolis.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1923Eli Lilly
Insulin Commercialization
Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1950Eli Lilly
Antibiotic Expansion
The company expands through antibiotics and broader prescription medicines.
1982Eli Lilly
Humulin Approved
Lilly introduces Humulin, one of the first recombinant DNA human insulin products.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2017Eli Lilly
David Ricks Becomes CEO
David A. Ricks becomes Chair, President, and CEO.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2019Eli Lilly
Loxo Oncology Acquired
Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Eli Lilly
Mounjaro Approved
Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023Eli Lilly
Zepbound Approved
Zepbound receives U.S. approval for chronic weight management.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Eli Lilly
Revenue Reaches $65.179B
Lilly reports $65.179B in 2025 revenue and $20.640B in net income.
2025Eli Lilly
First $1 Trillion Drugmaker
Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026Eli Lilly
Foundayo Approved
FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Eli Lilly
- Morphic Holding2024$3.2B
- POINT Biopharma2023$1.4B
- Prevail Therapeutics2021$1B
- Loxo Oncology2019$8B
- Elizabeth Arden1971Undisclosed
Questions about Bristol-Myers Squibb vs Eli Lilly
Who is the CEO of Bristol-Myers Squibb Company and Eli Lilly and Company?
Bristol-Myers Squibb Company is led by Christopher Boerner and Eli Lilly and Company is led by David A. Ricks. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Eli Lilly and Company?
Eli Lilly and Company was founded in 1876 — 11 years before Bristol-Myers Squibb Company, which was founded in 1887. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Bristol-Myers Squibb Company.
How many employees does Bristol-Myers Squibb Company have compared to Eli Lilly and Company?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Eli Lilly and Company employs approximately 50,000. Eli Lilly and Company has the larger workforce at 50,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Eli Lilly and Company headquartered?
Both Bristol-Myers Squibb Company and Eli Lilly and Company are headquartered in United States. Their local rules and tax obligations may still differ.
Who founded Bristol-Myers Squibb Company and Eli Lilly and Company?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Eli Lilly and Company was founded by Colonel Eli Lilly.
Which company has a longer operating history — Bristol-Myers Squibb Company or Eli Lilly and Company?
Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. Bristol-Myers Squibb Company has been in operation for around 139 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Eli Lilly overview